8-K: Vivos Therapeutics Secures New US Patent for Sleep Apnea Technology

Vivos Therapeutics announced the issuance of a new US Patent (No. 12,697,190) that broadens protection for its Vivos CARE oral medical device technology, a continuation of its 2024 foundational patent.

Summary

• Vivos Therapeutics has been issued a new US Patent, No. 12,697,190, titled 'Vibrational Oral Appliance with Mandibular Advancements'.
• This new patent is a continuation of a previous patent (No. 12,048,608) issued on July 30, 2024.
• Together, these patents enhance the protection for Vivos' proprietary Vivos CARE oral medical devices.
• The company's Vivos CARE devices have received FDA 510K clearances for treating severe OSA in adults and moderate to severe OSA in children (ages 6-17).
• Studies indicate that approximately 80% of patients treated with Vivos CARE devices experience significant reductions or complete resolution of OSA symptoms.
• The company highlights the growing market for alternatives to CPAP due to recalls and identified health risks associated with CPAP devices.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive development, as the issuance of a new patent strengthens the company's intellectual property portfolio and competitive position in a growing market.

Positives

• Issuance of a new US Patent (No. 12,697,190) strengthens intellectual property protection.
• The new patent broadens the scope of protection, providing layered and complementary coverage over Vivos technology.
• The Vivos CARE devices have received unprecedented FDA 510K clearances for both adult and pediatric OSA.
• Approximately 80% of patients treated with Vivos CARE devices show significant improvement in OSA symptoms.
• The company is well-positioned to capitalize on the market shift away from CPAP due to its safety concerns and recalls.

Negatives

• The new patent's practical value in protecting intellectual property and claims is subject to risk.
• There is a risk that the patents could be challenged, invalidated, narrowed, circumvented, or held unenforceable.
• New or competing technologies could diminish the economic value of the new patents.
• The company may face challenges in effectively marketing products covered by the new patent or increasing revenues.

Risks

• The newly issued continuation patent may have limited practical value in protecting intellectual property and claims.
• The 190 Patent or the 608 Patent may be challenged, invalidated, narrowed in scope, circumvented, or held unenforceable.
• Third parties may not be successful in enforcing or defending such patents.
• New or competing technology may limit or extinguish the new patents' economic value.
• Vivos may be unable to effectively market the products covered by the new patent or implement revenue-increasing strategies.
• Risks associated with regulatory scrutiny and adverse publicity in the sleep apnea and sleep disorder diagnosis and treatment sector.
• The company may be unable to secure additional financing to continue operations, acquire sleep center practices, or maintain its Nasdaq listing.
• Market and other conditions could impact Vivos' business or ability to obtain financing.

Future Outlook

The company believes that broadening patent protections will strengthen its industry-leading position and technological advantages. The new patent is expected to make it harder for competitors to design around Vivos' technology and reflects ongoing investment in protecting the science behind better patient outcomes.

Management Comments

• "We believe this new patent meaningfully strengthens our intellectual property position around the technology at the heart of our most important and advanced product lines."
• "Broader, more resilient patent claims make it harder for competitors to design around our innovations, and they reflect the continued investment were making in protecting the science behind better outcomes for patients suffering from OSA."

Industry Context

StockSavvy.ai notes that the issuance of this patent comes at a time when there is increasing scrutiny and recall activity surrounding CPAP machines, creating a potentially larger market opportunity for alternative treatments like Vivos' oral appliances.

Stakeholder Impact

• Shareholders may benefit from a strengthened competitive position and potential market share gains.
• Patients suffering from OSA may have access to more robust and protected treatment options.
• Competitors may face increased challenges in developing similar technologies due to enhanced patent protection.

Next Steps

• Continue to invest in protecting the science behind better outcomes for patients suffering from OSA.
• Leverage strengthened intellectual property position to maintain industry leadership and technological advantages.

Key Dates

Recommendation

The patent issuance is a positive development for Vivos Therapeutics, strengthening its intellectual property and competitive stance in the growing sleep apnea market. However, the company faces significant risks related to patent enforceability, competition, and future financing. While the news is encouraging, it does not yet provide sufficient evidence for a strong buy or sell recommendation, making 'hold' appropriate pending further operational and financial developments.

Keywords

Obstructive Sleep Apnea, Oral Appliance, Medical Device, Intellectual Property, Patent, FDA Clearance, Sleep Disorder, Mandibular Advancement